Medtech
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
Sigyn is not only trying to treat the inflammatory mediators that fuel sepsis; it wants to prevent the life-threatening event from occurring altogether.
The latest warning letter asks Medtronic to update its systems and procedures in order to deliver safe and high-quality devices to consumers.
A week after announcing its intention to spin off its consumer health division, J&J revealed ambitious plans for its pharmaceutical business.
Johnson & Johnson is planning to break off its consumer products business from its pharmaceutical and medical device businesses. They will become two publicly traded companies.
Although California is already a well-known hotbed for science and technology, the pandemic still precipitated a surge of activity in the life sciences industry.
The deal, which includes an upfront payment of $1.75 billion, enables Boston Scientific to expand its electrophysiology and structural heart product portfolio.
French artificial heart maker Carmat announced Tuesday that it had successfully implanted its Aeson artificial heart into the chest cavity of a 57-year-old woman.
Chin, 57, and Humad, 36, along with the company, were indicted on charges of paying surgeons to use their spinal implants in surgeries.
PRESS RELEASES